Chalcogen Hetero Ring Attached Directly Or Indirectly To The Piperazine Ring By Nonionic Bonding Patents (Class 514/254.07)
-
Publication number: 20090233843Abstract: Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.Type: ApplicationFiled: January 10, 2006Publication date: September 17, 2009Applicant: Cortendo Invest ABInventor: Per Marin
-
Publication number: 20090226500Abstract: Sutures are used in combination with anti-scarring agents to inhibit fibrosis between the sutures and the host tissues into which the sutures are inserted. Compositions and methods are described for use in reducing excessive scarring, surgical adhesion, and other disorders.Type: ApplicationFiled: January 31, 2007Publication date: September 10, 2009Applicant: Angiotech Pharmaceuticals, IncInventors: Rui Avelar, Arpita Maiti, Philip M. Toleikis, Johanne Diane Cashman, David M. Gravett
-
Publication number: 20090214656Abstract: A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>?Htr (1) (wherein ?Htr represents the endotherm (J/g) accompanying a transition at about 240° C). The solid dispersion product shows an improved bioavailability.Type: ApplicationFiled: August 8, 2006Publication date: August 27, 2009Applicants: ABBOTT GMBH & CO. KG, BARRIER THERAPEUTICSInventors: Gunther Berndl, Matthias Degenhardt, Markus Mäegerlein, Gerrit Dispersyn
-
Publication number: 20090203669Abstract: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamo-pituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.Type: ApplicationFiled: November 13, 2006Publication date: August 13, 2009Inventor: Nicholas E. Goeders
-
Publication number: 20090203713Abstract: Compounds, compositions, kits and methods for modulating hedgehog pathway activity, and treating conditions related to abnormal or aberrant hedgehog pathway activity, are disclosed.Type: ApplicationFiled: August 22, 2006Publication date: August 13, 2009Inventors: Philip A. Beachy, Jun O. Liu
-
Publication number: 20090197896Abstract: The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.Type: ApplicationFiled: February 2, 2008Publication date: August 6, 2009Inventors: Meidong Yang, Haigang Chen
-
Publication number: 20090176795Abstract: Tetrahydrofuran antibiotics formulated with certain diacylglycerol-poltethyleneglycol (DAG-PEG) lipids have increased water solubility and bioavailabilty. PEG-12 GDO, PEG-12 GDLO, PEG-12 GDM and PEG-12 GDP are particularly suitable for forming liposomes that incorporate tetrahydroflurans in the bilayer.Type: ApplicationFiled: January 4, 2008Publication date: July 9, 2009Inventors: Brian Charles Keller, Nian WU
-
Publication number: 20090169644Abstract: Surfactant-containing cleansing compositions contain hydrogenated castor oil for stabilizing an antidandruff component that is insoluble in the cleansing composition. As a result, thorough and gentle cleansing of skin and/or of hair with simultaneous antidandruff effect is ensured, without phase separation, change in viscosity, or reduction in the foaming ability during storage. Optimally, it is possible to dispense with additional stabilization of the antidandruff component through the use of gel formers.Type: ApplicationFiled: January 9, 2009Publication date: July 2, 2009Applicant: Henkel AG & Co. KGaAInventors: Dieter Goddinger, Thomas Schroeder
-
Patent number: 7550445Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.Type: GrantFiled: June 14, 2006Date of Patent: June 23, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Manoj Nerurkar, Vijay Naringrekar
-
Publication number: 20090155383Abstract: A personal care composition utilizing undecyl sulfates and/or ethoxylated undecyl sulfates (undeceth sulfates).Type: ApplicationFiled: October 22, 2008Publication date: June 18, 2009Inventors: David Johnathan Kitko, Howard David Hutton, III, Eric Scott Johnson, Thomas Allen Hutchins
-
Publication number: 20090149473Abstract: A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content of less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of a patient requiring such treatment an antifungal composition.Type: ApplicationFiled: December 2, 2008Publication date: June 11, 2009Applicant: STIEFEL RESEARCH AUSTRALIA PTY LTD.Inventors: Greg Davey, Albert Zorko Abram
-
Publication number: 20090118300Abstract: Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.Type: ApplicationFiled: April 10, 2007Publication date: May 7, 2009Inventors: Richard Berger, Scott Edmondson, Hansen Alexa, Cheng Zhu
-
Publication number: 20090098200Abstract: Compositions are provided comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic balance or a hydrophilic polymer, and the active lipophilic compound has modified physicochemical properties. The composition forms colloidal nanodispersion upon contact with aqueous media.Type: ApplicationFiled: September 25, 2008Publication date: April 16, 2009Applicant: SOLUBEST LTD.Inventors: Galia Temtsin Krayz, Maryana Averbuch, Ilya Zelkind, Larisa Gitis
-
Publication number: 20090099202Abstract: External preparations for athlete's foot treatment capable of enhancing patient's compliance and capable of reducing the symptom of rubefaction, comprising an anti-trichophyton drug mixed with at least one compound selected from among 1-menthol, menthol analogue compounds and bactericidal compounds.Type: ApplicationFiled: December 18, 2008Publication date: April 16, 2009Inventors: Toshihiro Shirouzu, Youichi Kawamura, Hiroki Kawatsura, Mitsuhiko Tokunaga
-
Publication number: 20090098085Abstract: The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters or prodrugs thereof: which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.Type: ApplicationFiled: January 18, 2008Publication date: April 16, 2009Inventors: Ying SUN, Dong LIU, Yat Sun OR, Zhe WANG
-
Patent number: 7514438Abstract: Novel compounds, or pharmaceutically-acceptable salts, tautomers or prodrugs thereof, of Formula I wherein A, W, X, Z, R1-R3, and R8 are as defined in the specification, are provided. Also provided are methods of treating or preventing a melanin concentrating hormone-mediated disorder in a subject, comprising administering to a subject in need of such treatment or prevention a compound of Formula I.Type: GrantFiled: August 11, 2004Date of Patent: April 7, 2009Assignee: Amgen, Inc.Inventors: Christopher Hulme, Paul A. Tempest, Vu Van Ma, Thomas Nixey, Guity Balow
-
Publication number: 20090088443Abstract: The invention provides novel soluble conazole crystalline forms (e.g. itraconazole, posaconazole and saperconazole) that include salts, co-crystals and related solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, these conazole crystalline forms. Methods of using such compositions for the treatment or prevention of systemic and local fungal, yeast, and dermatophyte infections are also provided.Type: ApplicationFiled: September 19, 2008Publication date: April 2, 2009Inventors: Julius Remenar, Michael MacPhee, Matthew Peterson, Sherry Morissette, Orn Almarsson
-
Publication number: 20090087480Abstract: A pharmaceutical composition containing one or more antifungal agents selected from an arylamidine derivative represented by the general formula: (wherein R1 represents an amidino group that may be substituted with a hydroxyl group that may be protected with an acyl group, an amidino group that may be substituted with an alkoxy group that may be substituted, or an amidino group that may be substituted with an aralkyloxy group that may be substituted; R2 and R3 identically or differently represent a hydrogen atom or a halogen atom) or a salt thereof, an azole antifungal agent, a polyene antifungal agent, a candin antifungal agent and a fluoropyrimidine antifungal agent has a strong antifungal activity and is useful for the treatment of fungal infection. A method for using them in combination is useful as an excellent therapeutic method for fungal infection.Type: ApplicationFiled: April 5, 2006Publication date: April 2, 2009Applicant: Toyama Chemical Co., Ltd.Inventors: Nobuhiko Nomura, Hiroshi Nishikawa, Noritomo Fujino
-
Publication number: 20090082363Abstract: The present application describes deuterium-enriched posaconazole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: September 19, 2008Publication date: March 26, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090069342Abstract: The present invention relates to 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents. The present invention further relates to compositions comprising said Kv1.5 potassium channel inhibitors, and to methods for treating cardiac arrhythmia.Type: ApplicationFiled: November 6, 2008Publication date: March 12, 2009Applicant: WyethInventors: John Michael Janusz, Stephen Joseph Hodson, Gregory Kent Bosch, Ronald Eugene White, Benjamin E. Blass, Christopher M. Jackson, Neil T. Fairweather
-
Publication number: 20090068290Abstract: The present disclosure is directed to compositions, kits and methods for not only treating schizophrenia, e.g., maintaining, reducing and/or improving at least one symptom of schizophrenia, but also to achieving an absence of or a reduced presence of at least one side effect associated with schizophrenia therapy with a first-generation atypical antipsychotic.Type: ApplicationFiled: August 30, 2007Publication date: March 12, 2009Inventors: Michel Bourin, Daniel E. Casey, Steven G. Potkin, Mark Rapaport, John Newcomer, Paul P. Yeung, Sangeeta Raje, Jeff Paul, Saeed Ahmed, Luigi M. Barbato, Nathan A. Shapira, Roseline Pardue, Antje A. Winsemius, Michiel H. de Vries, Marc Debelle, Jens Heisterberg, Mette Krog Josiassen, Jette Buch Ostergard, Dorte Malling, Ellen B. Christensen
-
Publication number: 20090062244Abstract: Topical composition for enhanced local and systemic delivery of poorly soluble biologically active compounds, comprises of non-volatile solvent or mixture of solvents to dissolve active component, and moisture absorbent or mixture of sorbents to prevent precipitation or crystallization of insoluble material after applicationType: ApplicationFiled: September 4, 2007Publication date: March 5, 2009Inventors: Joseph Schwarz, Michael Weisspapir
-
Publication number: 20090053290Abstract: Transdermal delivery compositions and topical compositions for application to the skin are provided. The transdermal delivery composition includes at least two penetrants working synergistically but by disparate biochemical pathways. In one embodiment, the transdermal delivery system includes benzyl alcohol and lecithin organogel. The transdermal delivery compositions are used in a variety of topical compositions as a means of transdermally delivering and topically administering different drugs and agents, including compositions promoting collagen biosynthesis, retinoids and skin lighteners, chemical denervation agents such as BOTOX®, anti-fungal agents, anesthetics and non-steroidal anti-inflammatory drugs (NSAIDs). In addition, these topical compositions may be used in combination with non-ablative treatment modalities, such as microdermabrasion, laser-based skin remodeling and radio-frequency-based skin remodeling.Type: ApplicationFiled: March 8, 2007Publication date: February 26, 2009Inventors: Bruce J. Sand, Michael Babich, Ali Zendedel Haghighi
-
Patent number: 7482346Abstract: The present invention comprises alkylpiperazine- and alkylhomopiperazine carboxylates and their derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase (FAAH) enzyme inhibitors. These derivatives exert various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors. By inhibiting the metabolic activity of the FAAH enzyme, compounds often responsible for the onset of disease and other pathological conditions are not generated and the incidence of the disease is greatly reduced.Type: GrantFiled: August 22, 2006Date of Patent: January 27, 2009Assignee: Sanofi-AventisInventors: Ahmed Abouabdellah, Antonio Almario Garcia, Christian Hoornaert, Tak Adrien Li
-
Publication number: 20090011013Abstract: The present invention relates to a pharmaceutical composition comprising tacrolimus or an analogue thereof and a substance being a substrate for CYP3A4 and/or P-glycoprotein, oral solid dosage forms comprising the pharmaceutical composition such as tablets, methods for preparing the pharmaceutical composition and oral dosage forms and use of the pharmaceutical composition for preparing a medicament. The substance being a substrate for CYP3A4 and/or P-glycoprotein is preferably cyclosporine A. The invention further relates to treatment of a patient in need thereof by coadministration of the combination according to the invention. In a further aspect, the invention relates to the above combination further comprising a CYP3A4 inhibitor compound, preferably a compound naturally occurring in citrus juice, for example grapefruit juice, preferably a spiro ortho ester compound.Type: ApplicationFiled: October 9, 2006Publication date: January 8, 2009Applicant: LIFECYCLE PHARMA A/SInventors: Lisbet Bonlokke Ranklove, Jan Moller Mikkelsen
-
Publication number: 20080317737Abstract: A topical treatment for skin disorders and diseases comprising a combination of at least one antifungal agent and at least one hydroxy acid agent formulated into shampoos, creams, lotions, gels, sprays, foams, pads, films, patches, and solutions for treatment of skin disorders and diseases in both humans and animals.Type: ApplicationFiled: June 19, 2008Publication date: December 25, 2008Inventors: Bhiku Patel, D. Craig Woodward, Philip J. Gordon
-
Publication number: 20080312253Abstract: The present invention relates to a pharmaceutical composition containing a pyrazole derivative as an active ingredient, which has antagonistic activity against serotonin 5-HT3A and is effective for the prevention and treatment of central nervous system (CNS) diseases, including emesis, nausea, alcoholism, drug abuse, depression, compulsive neurosis, anxiety, seizure, Alzheimer's disease, Parkinson's disease, Huntington's chorea, psychosis, schizophrenia, suicidal tendency, sleep disorder, appetite disorder and migraine.Type: ApplicationFiled: June 13, 2008Publication date: December 18, 2008Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Ghil Soo Nam, Hye Whon Rhim, Ae Nim Pae, Kyung II Choi, Hyun Ah Choo, Seung Yeol Nah
-
Publication number: 20080306068Abstract: The present invention provides kinase inhibitors of Formula I:Type: ApplicationFiled: June 15, 2005Publication date: December 11, 2008Applicant: Eli Lilly and CompanyInventors: Tiechao Li, Mark Andrew Pobanz, Chuan Shih, Yong Wang, Boyu Zhong, Jesus Andres Blas, Alfonso De Dios, Beatriz Lopez De Uralde-Garmendia, Luisa Maria Martin Cabrejas
-
Publication number: 20080305173Abstract: The present inventive subject matter relates to amorphous drug beads comprising an amorphous active drug and an organic surfactant having improved solubility, absorption and wettability characteristics. The present inventive subject matter further relates to methods of preparing the amorphous drug beads, wherein molten drug beads are subject to a cooling step with or without shear.Type: ApplicationFiled: January 15, 2007Publication date: December 11, 2008Inventor: Beuford Arlie Bogue
-
Publication number: 20080292584Abstract: Disclosed herein are methods of using metaxalone. In one embodiment, the method comprises determining that a patient in need metaxalone therapy is taking a substance that is a n inhibitor or an inducer of a cytochrome p450 isozyme, wherein the cytochrome P450 is CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4, and adjusting administration to the patient of metaxalone or the substance to avoid an adverse event associated with metaxalone. In another embodiment, the method comprises informing a user that metaxalone ais metabolized by a cytochrome p450 isozyme, wherein the cytochrome P450 is CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product.Type: ApplicationFiled: May 28, 2008Publication date: November 27, 2008Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventors: Richard H. Roberts, Jie Du, Matthew W. Davis
-
Patent number: 7452890Abstract: Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S.Type: GrantFiled: September 7, 2006Date of Patent: November 18, 2008Assignee: Ortho McNeil Pharmaceutical, Inc.Inventors: Mary Pat Beavers, J. Guy Breitenbucher, Hui Cai, James P. Edwards, Cheryl A. Grice, Darin J. Gustin, Haripada Khatuya, Steven P. Meduna, Barbara A. Pio, Kevin L. Tays, Jianmei Wei
-
Publication number: 20080280922Abstract: The present invention concerns an intermittent dosing regimen for the treatment of obesity or the reduction of body weight wherein a pharmaceutical composition containing an apoB secretion/MTP inhibitor is administered to a subject in need thereof for a period of time, then withheld for a period of time, and again administered for a period of time. The intermittent regimen may be repeated depending on the response in the subject that is being sought.Type: ApplicationFiled: April 6, 2005Publication date: November 13, 2008Inventors: Marc Alois Celine Maria Engelen, Dagmar Theo Coleta Maria Hoeben
-
Publication number: 20080279812Abstract: The present disclosure provides methods for preventing or treating illness, improving responsiveness to immunization, and improving the efficacy of gene therapy in a patient by disrupting sex steroid signalling in the patient, wherein the bone marrow and other immune cell functionality is improved without, prior to, or concurrently with, thymic regeneration. In some embodiments, sex steroid signalling is interrupted or ablated in the patient by the administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines, anti-androgens, anti-estrogens, selective estrogen receptor modulators (SERMs), selective androgen receptor modulators (SARMs), selective progesterone response modulators (SPRMs), ERDs, aromatase inhibitors, or various combinations thereof.Type: ApplicationFiled: April 19, 2004Publication date: November 13, 2008Applicants: Norwood Immunology, Ltd., Monash UniversityInventors: Richard Lennox Boyd, Gabrielle Lianne Goldberg, Ann Patricia Chidgey, Jayne Suzanne Sutherland
-
Patent number: 7446107Abstract: The invention provides novel soluble conazole crystalline forms (e.g. itraconazole, posaconazole and saperconazole) that include salts, co-crystals and related solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, these conazole crystalline forms. Methods of using such compositions for the treatment or prevention of systemic and local fungal, yeast, and dermatophyte infections are also provided.Type: GrantFiled: August 26, 2004Date of Patent: November 4, 2008Assignee: Transform Pharmaceuticals, Inc.Inventors: Julius Remenar, Michael MacPhee, Matthew Peterson, Sherry Morissette, Orn Almarsson
-
Publication number: 20080260837Abstract: The present invention concerns methods of making physically stable aqueous suspensions of sparingly soluble to insoluble in water, active pharmaceuticals. More particularly, the invention provides an aqueous pharmaceutical suspension composition comprising an active pharmaceutical component which is sparingly soluble to insoluble in water; a water soluble, low viscosity grade cellulose polymer with a viscosity range of 3 mPa·s to 50 mPa·s as a surfactant; a suspending agent; and water.Type: ApplicationFiled: April 20, 2007Publication date: October 23, 2008Inventors: Ranga R. Namburi, Bala Murali K. Vattikuti, Ratna Prabha Mulamalla, Burgise F. Palkhiwala
-
Publication number: 20080261986Abstract: Pharmaceutical formulations suitable for iontophoresis thereof that provide enhanced iontophoretic delivery of an anti-fungal drug to at least one body surface are described. Also described are pharmaceutical formulations suitable for iontophoresis comprising terbinafine and methods for administering terbinafine to a body surface via iontophoresis. In one embodiment, the body surface includes a nail plate and/or the skin.Type: ApplicationFiled: March 27, 2008Publication date: October 23, 2008Inventors: Phillip M. Friden, Hyun Kim, Bireswar Chakraborty
-
Publication number: 20080255082Abstract: The invention provides a hair and/or scalp care composition comprising a terpenoid compound of formula (I), (II) or (III) in which R1 to R11 are each, independently, —H, —F, —Cl, —Br, —I, —OH, lower alkyl (e.g. C1-6 alkyl) or lower alkoxy (e.g. C1-6 alkoxy).Type: ApplicationFiled: February 21, 2006Publication date: October 16, 2008Inventors: Ranjit Bhogal, Jasveen Chugh, Helen Meldrum
-
Publication number: 20080234291Abstract: The present invention concerns an oral solution comprising the MTP inhibitor mitratapide or an pharmaceutically acceptable acid addition salt thereof, a process for preparing such solutions, and their use in the treatment of MTP-related disorders such as hyperlipidemia, obesity, or type II diabetes.Type: ApplicationFiled: January 18, 2005Publication date: September 25, 2008Inventors: Marc Karel Jozef Francois, Roger Carolus Augusta Embrechts, Willy Maria Albert Carlo Dries
-
Patent number: 7427620Abstract: The present invention relates to novel compounds, of the general formula (I), the N-oxide forms thereof, the salts thereof with pharmaceutically acceptable acids and the stereochemical isomers thereof, which are useful as antifungal agents; to pharmaceutical compositions containing such compounds as the active ingredient; to methods for the production of said compounds and the associated pharmaceutical compositions.Type: GrantFiled: October 14, 2004Date of Patent: September 23, 2008Assignee: Italfarmaco SPAInventors: Massimo Pinori, Maria Lattanzio, Daniela Modena, Paolo Mascagni
-
Publication number: 20080214568Abstract: The present invention relates to a pharmaceutical composition. The inventive pharmaceutical composition comprises: at least a first therapeutically-active substance which is selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone and the isomers, derivatives and mixtures thereof; and at least a second therapeutically-active substance which is an antifungal agent.Type: ApplicationFiled: May 15, 2006Publication date: September 4, 2008Applicant: ADVANCED SCIENTIFIC DEVELOPMENTSInventor: Adnane Remmal
-
Publication number: 20080207537Abstract: Application of a reducing agent followed by an oxidising agent to a nail substantially increases the permeability thereof, thereby enabling the passage of drugs across the nail.Type: ApplicationFiled: June 6, 2006Publication date: August 28, 2008Applicant: MedPharm LimitedInventors: Robert Turner, Marc Barry Brown, Stuart Allen Jones
-
Patent number: 7417046Abstract: Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S.Type: GrantFiled: September 7, 2006Date of Patent: August 26, 2008Assignee: Ortho McNeil Pharmaceutical, Inc.Inventors: Mary Pat Beavers, J. Guy Breitenbucher, Hui Cai, James P. Edwards, Cheryl A. Grice, Darin J. Gustin, Haripada Khatuya, Steven P. Meduna, Barbara A. Pio, Kevin L. Tays, Jianmei Wei
-
Publication number: 20080193499Abstract: Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.Type: ApplicationFiled: June 27, 2005Publication date: August 14, 2008Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Jun Liu, Curtis Chong, David J. Sullivan
-
Publication number: 20080193428Abstract: The present invention relates to the use of benzoic acid and/or its sodium salt in combination with saccharide(s) as active components in the manufacture of a vaginal composition for modulating vaginal flora and vaginal acidity, thereby maintaining the pH value of vaginal secretion within a range from 3.5 to 4.5; and the present invention further relates to a vaginal composition and a method for modulating and maintaining normal vaginal flora and vaginal acidity.Type: ApplicationFiled: April 27, 2006Publication date: August 14, 2008Applicants: Shenzhen Phlora Biotechnology Limited, HK Phlora Health Science & Technology Ltd.Inventors: Ruyun Zhou, Zhongming Zeng
-
Publication number: 20080182858Abstract: The present invention is directed to solvates and various polymorphic forms of (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride and pharmaceutical compositions thereof.Type: ApplicationFiled: December 11, 2007Publication date: July 31, 2008Inventor: Nancy Lee Redman-Furey
-
Publication number: 20080171013Abstract: Improved posaconazole-based compositions and methods of treating and preventing fungal infections, cancer or metastatic diseases are disclosed. In preferred aspects, the conjugates are PEG-posaconazole conjugates in which the PEG has a molecular weight of about 20,000 daltons.Type: ApplicationFiled: January 15, 2008Publication date: July 17, 2008Applicant: ENZON PHARMACEUTICALS, INC.Inventor: Hong Zhao
-
Publication number: 20080161276Abstract: The present invention relates to compositions containing a) at least one monoacyl lipid; b) at least one diacyl glycerol and/or tochopherol; and c) at least one fragmentation agent; and optionally an active agent. The compositions are capable of self-dispersing to provide colloidal non-lamellar particles upon contact with an aqueous fluid. The invention additionally provides a method for forming non-lamellar particles from such compositions, and pharmaceutical formulations containing the compositions, plus non-lamellar particles formable from the compositions.Type: ApplicationFiled: August 4, 2005Publication date: July 3, 2008Inventors: Markus Johnsson, Fredrik Joabsson, Fredrik Tiberg
-
Patent number: 7393850Abstract: Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S.Type: GrantFiled: September 7, 2006Date of Patent: July 1, 2008Assignee: Ortho McNeil Pharmaceutical, Inc.Inventors: Mary Pat Beavers, J. Guy Breitenbucher, Hui Cai, James P. Edwards, Cheryl A. Grice, Darin J. Gustin, Haripada Khatuya, Steven P. Meduna, Barbara A. Pio, Kevin L. Tays, Jianmei Wei
-
Publication number: 20080152731Abstract: The invention encompasses a formulation for hair loss prevention comprising a mixture of water and at least one nonpolar aprotic organic solvent and at least one hair loss preventive ingredient known to inhibit the hormonal mechanism underlying androgenetic hair loss and methods of using the same.Type: ApplicationFiled: October 26, 2007Publication date: June 26, 2008Inventor: Giuseppe Trigiante
-
Patent number: RE40387Abstract: The invention relates to methods of increasing the bioavailability of orally administered epothilones. Epothilones administered by the methods of the invention are sufficiently bioavailable to have a pharmacological effect. The invention further relates to pharmaceutical compositions, pharmaceutical dosage forms, and kits for use in the methods of the invention.Type: GrantFiled: June 9, 2005Date of Patent: June 17, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Rebanta Bandyopadhyay, Timothy M. Malloy, Andrea Panaggio, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia, Marvin Barry Cohen